Celltrion Pharm Valuation
Is A068760 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of A068760 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate A068760's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate A068760's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A068760?
Key metric: As A068760 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is A068760's PB Ratio? | |
|---|---|
| PB Ratio | n/a |
| Book | ₩302.75b |
| Market Cap | ₩2.37t |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does A068760's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 6.7x | ||
A009420 Hanall Biopharma | 11.4x | 93.9% | ₩1.9t |
A000250 Sam Chun Dang Pharm | 9.4x | n/a | ₩2.6t |
A237690 ST PharmLtd | 4.1x | 40.1% | ₩1.7t |
A069620 Daewoong Pharmaceutical | 1.9x | 17.2% | ₩1.5t |
A068760 Celltrion Pharm | n/a | n/a | ₩2.4t |
Price-To-Book vs Peers: Insufficient data to calculate A068760's Price-To-Book Ratio vs. peers for valuation analysis.
Price to Book Ratio vs Industry
How does A068760's PB Ratio compare vs other companies in the KR Pharmaceuticals Industry?
| 0 Companies | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
| 0 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Book vs Industry: Insufficient data to calculate A068760's Price-To-Book Ratio vs. industry for valuation analysis.
Price to Book Ratio vs Fair Ratio
What is A068760's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | n/a |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate A068760's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Hugel
₩3.0t
Develops and manufactures biopharmaceuticals in South Korea and internationally.
A145020
₩273,500.00
7D
0.9%
1Y
75.3%
J2KBIO
₩52.9b
A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.
A420570
₩9,260.00
7D
-5.8%
1Y
n/a
Medy-Tox
₩883.1b
Operates as a biopharmaceutical company in South Korea.
A086900
₩131,200.00
7D
1.7%
1Y
-39.0%